For example, cancer patients genetically predisposed with decreased UGT1A1 activity are at higher risk for severe toxicity when treated with anti-cancer agents such as irinotecan used in metastatic colorectal cancer. This evidence concerns the gene UGT1A1 and metastatic colorectal cancer.